TScan Therapeutics, Inc. - Voting Common Stock, $0.0001 par value per share (TCRX)

CUSIP: 89854M101

Q2 2025 13F Holders as of 30 Jun 2025

Holder snapshot 6 signals
Share change
-4,382,817
SEC-reported price per share
$1.45
Number of holders
79
Value change
-$5,881,550
Number of buys
46
Number of sells
49
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
63,951,630

Security key

89854M101

Report period

Q2 2025

Institutions

79

Top holders

10

Ownership snapshot

Top reported holders of TCRX - TScan Therapeutics, Inc. - Voting Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ADAGE CAPITAL PARTNERS GP...
Disclosed value leader
EcoR1 Capital, LLC
Comparable rows
5/15
Latest evidence
30 Jun 2025
13D/G 13F 3/4/5 Lead comparable stake: 7.1% 10 rows are not safely comparable across share classes. 13D/G row: ADAGE CAPITAL PARTNERS GP, L.L.C. Showing 1-6 of 15 holder rows.

Quick read

ADAGE CAPITAL PARTNERS GP, L.L.C. leads the comparable SEC ownership view at 7.1%.

5 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ADAGE CAPITAL PARTNERS GP, L.L.C.'s linked filing trail.
Comparable ownership Top 5
ADAGE CAPITAL PARTNERS GP, L.L.C. 7.1%
K2 HealthVentures Equity Trust LLC 6.9%
Adage Capital Management, L.P. 2.5%
BlackRock, Inc. 1.8%
EcoR1 Capital, LLC 1.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ADAGE CAPITAL PARTNERS GP, L.L.C.
13D/G 13F
Adage Capital Management, L.P. · Company
7.1%
Reported 13D/G · 31 Dec 2024
$5,600,000
3,500,000 shares
$0 31 Dec 2024
K2 HealthVentures Equity Trust LLC
13D/G
6.9%
Reported 13D/G · 31 Dec 2024
$5,764,320
3,602,700 shares
$0 31 Dec 2024
Adage Capital Management, L.P.
13D/G
2.5%
Reported 13D/G · 30 Jun 2025
$1,957,500
1,350,000 shares
$0 30 Jun 2025
BlackRock, Inc.
13F 13D/G
Company
1.8%
Reported 13D/G · 30 Jun 2025
$6,732,789
4,878,833 shares
— 31 Mar 2025
EcoR1 Capital, LLC
3/4/5 13D/G 13F
10%+ Owner · Company
1.3%
Reported 13D/G · 31 Mar 2025
$24,842,500
5,000,000 shares
— 26 May 2023
Christoph H. Westphal
3/4/5
10%+ Owner
—
denominator unverified
$10,898,266
2,193,472 shares
— 20 Jul 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
79
Shares
35,724,879
Rows available
79
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2025 vs Q2 2026 Across Filers

Q2 2026 holders
59
Q2 2025 holders
79
Holder diff
20
Investor Q2 2026 Shares Q2 2025 Shares Share Diff Share Chg % Q2 2026 value Q2 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .